Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma
Juichi Takada(Kitasato University), Wasaburo Koizumi(Kitasato University), Satoshi Kobayashi(Kanagawa Cancer Center), Takahide Nakazawa(Kitasato University Hospital), Masaaki Kondo(Yokohama City University Medical Center), Kotaro Matsunaga(St. Marianna University School of Medicine), Katsuaki Tanaka(Yokohama City University Medical Center), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Chiaki Okuse(St. Marianna University School of Medicine), Hisashi Hidaka(Kitasato University), Shinichi Ohkawa(National Cancer Center Hospital East), Kazushi Numata(Yokohama City University Medical Center)
Cited by 43
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.
|Journal of Biological Chemistry|1990|625
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation.
|Proceedings of the National Academy of Sciences|1981|586